Biotech | March 16, 2022
Sanofi announces €300 million collaboration with Blackstone Life Sciences
The investment will accelerate the overall Sarclisa development program
The investment will accelerate the overall Sarclisa development program
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Tislelizumab is now approved for seven indications in China
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Subscribe To Our Newsletter & Stay Updated
